A dramatic course after the resection of an SMARCA4-deficient undifferentiated tumour.
Respirol Case Rep
; 10(8): e01001, 2022 Aug.
Article
in En
| MEDLINE
| ID: mdl-35822082
ABSTRACT
Thoracic SMARCA4-deficient undifferentiated tumours are ordinarily found as a huge mass with systemic metastasis, and the prognosis is poor. The potential of immunotherapy for these unresectable tumours has been reported. An asymptomatic 68-year-old man with a smoking history had a left lung mass without distant metastasis and underwent complete resection. Two months after surgery, with no adjuvant therapy, he developed multiple distant metastases with aphasia and died 4 months after surgery. Adjuvant treatment may be necessary with immune checkpoint inhibitors, with a closer follow-up to detect recurrence without symptoms.
Full text:
1
Database:
MEDLINE
Type of study:
Prognostic_studies
Language:
En
Year:
2022
Type:
Article